Neurogene (NASDAQ:NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy ...

Neurogene (NGNE) announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of ...

Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the pharmaceutical company’s shares to drop massively in after-hours trading ...

Neurogene's stock {$NGNE} fell 35% in post-market trading on Monday after a Rett syndrome patient who received a high dose of ...

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Neurogene (NGNE – Research Report), with a price target of $60.00. The company’s shares closed ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Failed nano cap Aquinox Pharma merged with Neuleukin in 2019 to become Neuleukin; Neuleukin failed in 2022 and merged with Neurogene (NASDAQ:NGNE) to become Neurogene in December 2023. Through ...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases ...

Shares of NASDAQ NGNE opened at $48.37 on Wednesday. The business has a 50-day moving average of $42.11 and a two-hundred day moving average of $38.22. Neurogene has a 1 year low of $12.49 and a 1 ...